TABLE 2.
Demographics, Clinicopathological, and Pathological Findings in 145 aSyn Cases Without Concomitant Alzheimer Disease, Grouped by USSLB Stage
| I | IIa | IIb | III | IV | Total | p | |
|---|---|---|---|---|---|---|---|
| n (% of total) | 10 (6.9%) | 32 (22.1%) | 12 (8.3%) | 63 (43.4%) | 28 (19.3%) | 145 | |
| Male, n (%) | 6 (60%) | 20 (62.5%) | 6 (50.0%) | 42 (66.7%) | 14 (50.0%) | 88 (60.7%) | 0.5738* |
| Age at death (mean + SD) | 86.1 + 5.9 | 86.3 + 7.3 | 87.3 + 10.2 | 79.8 + 6.5 | 80.6 + 7.2 | 82.5 +7.7 | <0.0001† |
| Time interval between last clinical assessment and autopsy (days)(mean + SD) | 342.1 (203.0) | 302.6 (253.4) | 468.9 (194.5) | 225.0 (202.1) | 335.1 (243.1) | 292.0 (230.2) | 0.0065† |
| Final cognitive status | 0.0013‡ | ||||||
| CogNL | 7 (70.0%) | 22 (68.8%) | 8 (66.7%) | 29 (46.0%) | 6 (21.4%) | 72 (49.7%) | |
| MCI | 2 (20.0%) | 5 (15.6%) | 3 (25.0%) | 8 (12.7%) | 6 (21.4%) | 24 (16.6%) | |
| Dementia | 1 (10.0%) | 5 (15.6%) | 1 (8.3%) | 26 (41.3%) | 16 (57.1%) | 49 (33.8%) | |
| Final clinicopathologic diagnosis | <0.0001‡ | ||||||
| ILBD | 8 (80.0%) | 22 (68.8%) | 7 (58.3%) | 8 (12.7%) | 0 (0%) | 45 (31.0%) | |
| PD | 0 (0.0%) | 10 (31.2%) | 5 (41.7%) | 50 (79.4%) | 28 (100%) | 93 (64.1%) | |
| DLB | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (3.2%) | 0 (0.0%) | 2 (1.4%) | |
| PSP | 1 (10%) | 0 (0.0%) | 0 (0.0%) | 3 (4.8%) | 0 (0.0%) | 4 (2.8%) | |
| Dementia NOS | 1 (10%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (0.7%) | |
CogNL, cognitively normal; MCI, mild cognitive impairment; ILBD, incidental Lewy body disease; Parkinson’s disease; DLB, dementia with Lewy bodies; PSP, progressive supranuclear palsy; Dementia NOS, no clear pathology to explain the dementia.
*
Chi-square p value.
†
ANOVA F-test p value.
‡
Fisher exact p value.